Partner Notification, Treatment, and Subsequent Condom Use After Pelvic Inflammatory Disease: Implications for Dyadic Intervention With Urban Youth

Clin Pediatr (Phila). 2019 Oct;58(11-12):1271-1276. doi: 10.1177/0009922819852979. Epub 2019 Jun 5.

Abstract

Research suggests that youth in urban communities often remain in the same sexual relationships after a pelvic inflammatory disease (PID) diagnosis. Utilizing data from the Technology Enhanced Community Health Nursing (TECH-N) study, we explored partner notification, treatment, and condom use after PID diagnosis. Outreach interviews assessed adherence to self-care behaviors, followed by interviews 3 months after diagnosis. Descriptive statistics and multivariable logistic regressions evaluated baseline condom use versus 3 months after diagnosis as it relates to group and relationship status. Ninety-one percent reported partner notification, and of those notified, 90% reported partner treatment. Reports of condom use increased in both groups compared with baseline use. TECH-N participants were more likely to report condom use at last sex at 3 months compared with baseline. Given the open communication with partners about PID and partner-associated effects on condom use, exploring dyadic intervention to promote consistent, condom use after PID for youth in high STI (sexually transmitted infection) prevalence communities is required.

Trial registration: ClinicalTrials.gov NCT01640379.

Keywords: STI; adolescents; condom use; partner notification and treatment; pelvic inflammatory disease.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adolescent Behavior*
  • Anti-Bacterial Agents / therapeutic use*
  • Condoms / statistics & numerical data*
  • Contact Tracing / statistics & numerical data*
  • Female
  • Humans
  • Interviews as Topic
  • Male
  • Pelvic Inflammatory Disease / drug therapy*
  • Pelvic Inflammatory Disease / epidemiology*
  • Sexual Partners
  • Urban Population

Substances

  • Anti-Bacterial Agents

Associated data

  • ClinicalTrials.gov/NCT01640379